Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, was selected as one of the Top 40 Milestone 1 award winners for the $101 Million XPRIZE Healthspan Competition. Award-winning teams will each receive $250,000 to help support them through the next phase of the competition and all semi-finalists will be recognized during the XPRIZE Healthspan Award Ceremony and Investor Summit in NYC (May 12-14).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512545779/en/
In the last 100 years, we have more than doubled the global average life expectancy, but the number of those years that are spent in good health has not kept pace. XPRIZE Healthspan aims to address this issue and revolutionize the way the world approaches human aging through its 7-year, $101 Million global competition. Competing teams are developing and testing novel therapeutics to restore muscle, cognition and immune function by a minimum of 10 years with a goal of 20 years in persons aged 50-80 years, in one year or less.
At the summit, investors will have early, invitation-only access to supporting the world’s most transformative visions for the future of healthcare. Immunis was among the few teams chosen for an investor pitch on the mainstage during the formal event on May 13th, which will be delivered by the company’s Chairman and Team Lead, Dr. Hans Keirstead.
“Immunis is absolutely thrilled and deeply honored to be recognized as a promising healthcare innovator. The team is grateful for the opportunity to showcase our work among such esteemed peers. We are studying our investigational therapy in clinical trials now, fueled by the potential health benefits it could provide for humanity,” remarks Chairman Dr. Keirstead.
XPRIZE is the recognized global leader in designing and executing large-scale competitions to solve humanity’s greatest challenges. For 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future. Donate, learn more, and co-architect a world of abundance at XPRIZE.org.
Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived biologics for the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis’ leading-edge capabilities in stem cell secretome technology to deliver a product of all natural, all human immune modulators in their natural physiological concentrations.
For additional information about Immunis’ programs, please visit our Pipeline.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250512545779/en/
“Immunis is absolutely thrilled and deeply honored to be recognized as a promising healthcare innovator."
